The Drug-to-Antibody Ratio (DAR) is the most important quality attribute of ADC drugs because it determines the “payload” that can be delivered to tumors, directly impacting safety and efficacy. Here, we […]
In the early 21st century, after the completion of the Human Genome Project, it was discovered that many diseases were caused by gene mutations leading to insufficient expression of functional […]
Driven by increasingly mature technologies, ADC payloads have undergone three generations of innovation. In the first generation of ADC drugs, traditional chemotherapy agents such as methotrexate, vincristine, and doxorubicin were used […]
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the […]
Peptide Nucleic Acid (PNA) is a synthetic polymer similar to DNA or RNA. PNA can be said to have been born in Denmark, where it was originally developed by Peter E. […]
With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the […]
Aptamers are short RNA/DNA oligonucleotide molecules that bind specifically to complementary target molecules. As potential recognition elements, aptamers show promising applications in both diagnosis and treatment. They offer diverse therapeutic and diagnostic […]
CD137/4-1BB combination therapy
Paclitaxel is a natural anticancer drug with the molecular formula C47H51NO14. It has been widely used in the clinical treatment of breast cancer, ovarian cancer, and certain head and neck cancers, […]
Chemical drugs can be classified into three categories based on their binding modes: covalent drugs, non-covalent drugs, and covalent reversible drugs. Covalent drugs have strong binding ability and high efficacy, […]